

NanoLC-FTMS Based Mapping of Protein Oxidation Sites Using Element-Coded Affinity Mass Tags

N. L. Young

September 30, 2004

Federation of Analytical Chemistry and Spectroscopy Societies Portland, OR, United States October 3, 2004 through October 7, 2004

Disclaimer

This document was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor the University of California nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or the University of California, and shall not be used for advertising or product endorsement purposes.

NanoLC-FTMS Based Mapping of Protein Oxidation Sites Using Element-Coded Affinity Mass Tags

Nicolas L. Young

Lawrence Livermore National

Laboratory

Outline

- Protein Oxidation Background
- Analytical Approach & Instrumentation
- Identification of Protein Oxidation Sites in Serum
- Site Specific Quantitation
- Future Work

Protein Oxidation is Associated with Disease

Carbonyl end-products of protein oxidation

Have been correlated with:

Alzheimer's Disease

Cataractogenesis

Progeria

Werner's syndrome

Amyotrophic lateral sclerosis

Respiratory distress syndrome

Aging

Are thought to be associated with:

Atheroclerosis

Diabetes

Parkinson's disease

Essential hypertension

Cystic fibrosis

Ulcerative colitis

J. Biol. Chem 272, pp. 20313-20316

Mechanism of Oxidation


Metal ions bound in protein metal binding pockets, or free metals, catalyze the production of hydroxyl radicals which then damage surrounding amino acids, resulting in reactive aldehyde end products.

$$H_2N$$
 NH
 NH_2
 NH

The reactive aldehyde may cross-link proteins by forming a Schiff base with amines leading to aggregation.

J. Biol. Chem 272, pp. 20313-20316

Scheme to Identify & Quantitate Sites of Oxidation




ECAT Allows small or large Δm and potentially large mass defect differences and multiplexing

H_2N		
AOD - aminoo	xyamino	benzylDOTA

Isotope	Mass	%
89 Y	88.905856	100
¹³⁹ La	138.906355	99.91
¹⁴¹ Pr	140.907657	100
¹⁵⁹ Tb	158.92535	100
¹⁶⁵ Ho	164.930332	100
¹⁶⁹ Tm	168.934225	100
¹⁷⁵ Lu	174.940785	97.4

Element	¹³⁹ La	¹⁴¹ Pr	¹⁵⁹ Tb	¹⁶⁵ Ho	¹⁶⁹ Tm	¹⁷⁵ Lu
89Y	50.000499	52.001801	70.019494	76.024476	80.028369	86.034929
139La		2.001302	20.018995	26.023977	30.02787	36.03443
141Pr			18.017693	24.022675	28.026568	34.033128
159Tb				6.004982	10.008875	16.015435
165Ho					4.003893	10.010453
169Tm						6.00656

Instrumentation - NanoLC-FTICR MS




- Grounded Liquid Junction
- 75 µm I.D. Column incorporated in uncoated laser-pulled tip
- On-Axis Geometry
- Stable & Robust throughout gradient
- Sensitive spray ~ 100 zmol on column LLOD

Bruker Apex II 9.4T FTMS with Modified Apollo Source




 Eight transients co-added every 0.1 minutes yielding 2D LCMS data sets


LC-FTMS of Oxidized, Labeled and Affinity Purified HSA Digest




LC-FTMS of Oxidized, Labeled and Affinity Purified HSA Digest




LC-FTMS of Control - Labeled and Affinity Purified HSA Digest



LC-FTMS of Control - Labeled and Affinity Purified HSA Digest





Identified Peptides

rHSA Control


Sequence	Position
AACLLP*K	175-181
LDELRDEGK*ASSAK	182-195
FGER*AFK	206-212
TPVSDR*VTK	467-475

rHSA Oxidized


Sequence	Position	Present in Control?
FK*DLGEENFK	11-20	
DDNP*NLPR	107-114	
AACLLP*K	175-181	Y
FGER*AFK	206-212	Y
FPK*AEFAEVSK	223-233	5
LAK*TYETTLEK	349-359	
CCKHP*EAK	437-444	v C
TP*VSDR	467-472	
TPVSDR*VTK	467-475	Y

Pre-existing vs FeEDTA/Asc Oxidized


Control Front View




Control Rear View



Oxidized Front View





Oxidized Rear View





Relative Quantitation


Neat picture Here














Quantitation Summary

- Relative quantitation achieved
- Validated with reverse tagging experiment (Some experimental error observed)
- Oxidation site preference found (Potential for site specific biomarkers validated)

	Native Tb/Oxidized Tm	Oxidized Tm /Native Tb	Average
LD*E*LRD*E*GK	2.5	3.2	2.9
TPVSDR*VTK	11.5	8.0	
LDELRDEGK*ASSA	AK 1.6	3.5	2.6
LK*ECCEK*PLLEK	1.6	2.5	2.1
LAKTYETTLEK	2.8	1.7	2.3
YIC†ENQDSISSK*L	K 5.3	5.7	


HSA Oxidation: Conclusion

- All oxidized peptides mapped to protein surface (potential low resolution surface mapping technique ala H-D exchange)
- Knowledge of oxidized peptide not necessary for detection (can be understood after the fact)
- Use of tag specific antibodies enables low level detection of oxidized proteins in complex matrices such as serum.
- Relative quantitation achieved

Future Work

- Multiplexed quantitation of clinical samples
- Biomarker discovery using relative quantitation
- Intermolecular interactions (Protein-Protein)

Scheme to Extract Spatial Information Using FeBABE and Lanthanide DOTA Tags



Acknowledgements

LLNL

Dr. W. Henry Benner
Dr. Christopher G. Bailey

U.C. Davis

Dr. Claude F. Meares
Susan Lee*
Paul A. Whetstone
Nathaniel G. Butlin
Todd M. Corneillie
Sarah M. Cheal